KRAS and colorectal carcinoma: Similarly, although RAF inhibitors alone have shown limited success in KRAS-mutant CRC, combination strategies targeting RAF and MEK or RAF and EGFR are being explored to suppress MAPK signaling and potentially overcome resistance (Table 3).